Mol P - Search Results

1

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Weldegiorgis M, de Zeeuw D, Dwyer JP, Mol P, Heerspink HJL. Weldegiorgis M, et al. Among authors: mol p. Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1595-1600. doi: 10.2215/CJN.09590916. Epub 2017 Sep 18. Clin J Am Soc Nephrol. 2017. PMID: 28923834 Free PMC article.

2

Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in Europe.

Kallio MJ, Starokozhko V, Agricola E, Burggraf M, Heß A, Ballensiefen W, Löbker W, Nuevo Y, Pasmooij AMG, Mol PGM; STARS consortium. Kallio MJ, et al. Clin Pharmacol Ther. 2023 Feb;113(2):349-359. doi: 10.1002/cpt.2789. Epub 2022 Nov 21. Clin Pharmacol Ther. 2023. PMID: 36326573 Free PMC article.

3

[The new pharmacovigilance legislation in practice].

Broekmans AW, Mol PG. Broekmans AW, et al. Ned Tijdschr Geneeskd. 2014;158:A7129. Ned Tijdschr Geneeskd. 2014. PMID: 24846112 Dutch.

4

[Interaction between clopidogrel and proton pump inhibitors].

Harmsze AM, de Boer A, Boot H, Deneer VH, Heringa M, Mol PG, Schalekamp T, Verduijn MM, Verheugt FW, le Comte M. Harmsze AM, et al. Ned Tijdschr Geneeskd. 2011;155(28):A2442. Ned Tijdschr Geneeskd. 2011. PMID: 21771377 Review. Dutch.

5

Starokozhko V, Tarrahi F, Vrijlandt PJWS, Mol PGM. Starokozhko V, et al. Clin Pharmacol Ther. 2023 Apr;113(4):859-866. doi: 10.1002/cpt.2840. Epub 2023 Jan 18. Clin Pharmacol Ther. 2023. PMID: 36606727 Review.

6

Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation.

Cortoos PJ, Gilissen C, Mol PG, Van den Bossche F, Simoens S, Willems L, Leenaers H, Vandorpe L, Peetermans WE, Laekeman G. Cortoos PJ, et al. J Antimicrob Chemother. 2011 Dec;66(12):2864-71. doi: 10.1093/jac/dkr366. Epub 2011 Sep 15. J Antimicrob Chemother. 2011. PMID: 21926079

7

Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire.

de Vries ST, Mol PG, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. de Vries ST, et al. Among authors: mol pg. Drug Saf. 2013 Sep;36(9):765-77. doi: 10.1007/s40264-013-0036-8. Drug Saf. 2013. PMID: 23553447 Clinical Trial.

8

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.

Mol PGM, Thompson A, Heerspink HJL, Leufkens HGM. Mol PGM, et al. Diabetes Obes Metab. 2018 Oct;20 Suppl 3(Suppl Suppl 3):19-23. doi: 10.1111/dom.13453. Diabetes Obes Metab. 2018. PMID: 30294953 Free PMC article. Review.

9

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe.

Koomen JV, Stevens J, Monster-Simons MH, Heerspink HJL, Mol PGM. Koomen JV, et al. Front Pharmacol. 2021 Apr 28;12:626766. doi: 10.3389/fphar.2021.626766. eCollection 2021. Front Pharmacol. 2021. PMID: 33995023 Free PMC article.

10

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting.

Bakker E, Mol PGM, Nabais J, Vetter T, Kretzler M, Nolan JJ, Mayer G, Sundgren AK, Heerspink HJL, Schiel A, de Vries ST, Gomez MF, Schulze F, de Zeeuw D, Pena MJ; BEAt-DKD Consortium. Bakker E, et al. Front Pharmacol. 2021 May 4;12:662642. doi: 10.3389/fphar.2021.662642. eCollection 2021. Front Pharmacol. 2021. PMID: 34025424 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

280 results

Search Page